Brainsway (BWAY) Earnings Date & Reports

Key Takeaways

• BrainsWay reported third-quarter 2026 revenue of $18.1 million, up 34% from $13.5 million in the prior-year period.
• Gross margin expanded to 78%, up from 75% a year earlier, while operating income rose 107% to roughly $2.6 million.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) nearly doubled to $3.9 million, lifting the margin to 21% from 15%.
• The company shipped 130 Deep TMS systems, pushing its installed base above 2,000 devices, with remaining performance obligations up 31% to about $85 million.
• Management now expects full-year 2026 results to land at the upper end of prior guidance, with potential to modestly exceed those ranges.
• For more context, explore Major News, Today's Price Move, Price Targets, and Forecast on Tickeron's dedicated BWAY pages.
• Looking for new trade ideas? Discover Trending AI Robots to see AI-driven strategies that scan the market in real time.

Earnings Context and Why It Matters

BrainsWay is a global leader in noninvasive neurostimulation treatments for mental health disorders, anchored by its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform. The third quarter matters because it tests whether the company can keep converting its growing installed base into profitable, recurring revenue. With reimbursement coverage for its accelerated "SWIFT" protocol expanding rapidly in the U.S., investors are watching closely to see whether demand and margins are scaling together. Strong top-line growth paired with widening profitability would reinforce BrainsWay's shift toward a more predictable, subscription-like business model and support the case for continued operating leverage heading into 2027.

Reported Results

For the third quarter of 2026, BrainsWay reported revenue of $18.1 million, a 34% increase from $13.5 million in the same period last year and modestly above consensus estimates. Gross profit climbed 39% to $14.1 million, with gross margin reaching 78%. Operating income increased 107% to approximately $2.6 million, expanding operating margin to 14% of revenue from 9% a year ago.

Net income rose 42% to $2.2 million, though finance expenses tied to periodic loan valuation weighed on the bottom line. Adjusted EBITDA jumped 92% to $3.9 million. The company shipped 130 Deep TMS systems, up 44% year over year, and ended the quarter with remaining performance obligations of about $85 million, up 31%. Operating cash flow reached $6.2 million, and the company's cash position stood at roughly $63.4 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters covering industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. If you are researching names like BrainsWay, the AI Screener can help you compare peers and spot setups worth watching.

Market Reaction and Investor Sentiment

Reaction to the print was mixed. While revenue topped estimates, reported earnings per share came in below some consensus figures, and shares pulled back following the release. Investors appear to be weighing a modest bottom-line shortfall against a quarter where nearly every operating indicator improved, including margins, system shipments, backlog, and cash flow. The key tension for the market is whether accelerating expense growth, driven in part by one-time share-based compensation costs, will continue to outpace the strong top-line expansion. Sentiment remains supported by the company's swelling remaining performance obligations and its increasingly profitable, recurring revenue model.

Forward Outlook and Key Factors to Monitor

BrainsWay enters the final stretch of 2026 with raised visibility. Management indicated full-year results should reach the upper end of its existing guidance range, with the potential to modestly exceed it. The central question for investors is whether profitability can keep expanding as the company invests in commercial, clinical, and product development initiatives.

Several items are worth watching next. First, reimbursement trends remain the most important catalyst: coverage for the SWIFT accelerated protocol has surpassed 70 million covered lives in the U.S., and management noted that roughly half of new demand now involves the protocol. Further expansion of obsessive-compulsive disorder (OCD) coverage and adolescent depression clearance could widen the addressable market.

Second, operating-expense discipline will be scrutinized after a quarter that included roughly $1 million in one-time items. Third, the company's strategic investment program, including its minority stakes in mental-health clinic operators and its investment in home-based neuromodulation developer Neurolief, bears watching for how it influences future revenue and cash deployment. Finally, any regulatory updates on additional indications and the trajectory of book-to-bill orders will help confirm whether the current growth pace is sustainable into 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations